These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34116676)

  • 1. Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    BMC Pediatr; 2021 Jun; 21(1):272. PubMed ID: 34116676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    BMC Pediatr; 2020 Jun; 20(1):314. PubMed ID: 32593299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic analysis of E2F transcription factors E2F1 and E2F3 in four independent pediatric neuroblastoma cohorts.
    Wang H; Wang X; Xu L; Zhang J
    BMC Pediatr; 2022 Jun; 22(1):376. PubMed ID: 35764946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting amplification of
    Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
    Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in
    Zhao M; Gu W; Liu F; Yu L; Shu Y; Liu L; Hu J; Liu Y; Tang H; Mao J
    Pediatr Dev Pathol; 2023; 26(2):124-132. PubMed ID: 36775958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma].
    Fan X; Lu HT; Hou L; Zhang L; Yang BY; Chen WM; Zhang HY; Chen X; Li FJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2020 Mar; 22(3):262-268. PubMed ID: 32204764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXR2 Stabilizes MYCN Protein and Identifies Non-
    Schmitt-Hoffner F; van Rijn S; Toprak UH; Mauermann M; Rosemann F; Heit-Mondrzyk A; Hübner JM; Camgöz A; Hartlieb S; Pfister SM; Henrich KO; Westermann F; Kool M
    J Clin Oncol; 2021 Oct; 39(29):3217-3228. PubMed ID: 34110923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
    Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
    BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
    Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.
    Wang H; Wang X; Xu L
    Ital J Pediatr; 2023 Oct; 49(1):145. PubMed ID: 37904225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYCN protein stability is a better prognostic indicator in neuroblastoma.
    Yang Y; Zhao J; Zhang Y; Feng T; Yv B; Wang J; Gao Y; Yin M; Tang J; Li Y
    BMC Pediatr; 2022 Jul; 22(1):404. PubMed ID: 35820898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.